As healthcare systems across emerging markets face growing pressure, access to high-cost therapies increasingly depends not only on clinical innovation, but on how care is financed. In this white paper, Simon-Kucher explores how pharmaceutical companies can rethink access strategies by building sustainable financing ecosystems that expand affordability, improve patient outcomes, and unlock long-term growth.
Drawing on real-world examples and deep expertise across life sciences and healthcare, the paper outlines how private health insurance models, partnership ecosystems, and alternative financing approaches can help bridge the access gap in LMICs and beyond.
Key insights include:
- Why financing, not innovation, is becoming the key access bottleneck
- The strategic framework of “Who pays” vs. “How we pay”
- Emerging private-sector financing models shaping access today
- What it takes to build scalable and sustainable financing ecosystems
- How pharma companies can embed innovative financing into access and launch strategies
Discover how leading organizations are moving beyond pricing alone to create scalable, patient-centered access models that work across stakeholders and healthcare systems.
